About 14,400 results
Open links in new tab
  1. Novo Nordisk | Unordinary drives change

    Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.

  2. Careers - Novo Nordisk

    At Novo Nordisk, you will have the opportunity to build a life-changing career in a global business environment. Join us and make a difference.

  3. Who we are - Novo Nordisk

    Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in discovering and developing treatment for serious chronic disease, like diabetes …

  4. Our medicines | Diabetes medications | Obesity medication - Novo …

    Patient safety is our top priority, and we are committed to supporting the active fight against falsified Novo Nordisk medicines and other illegal activity in the market.

  5. What we do - Novo Nordisk

    Novo Nordisk is a global healthcare company with more than 100 years of innovation and leadership in serious chronic disease treatment.

  6. News Details - Novo Nordisk

    To see all the news please click on the button below. See the latest news NOVO NORDISK HQ Novo Nordisk A/S Novo Alle 1 2880 Bagsværd Denmark

  7. Latest news - Novo Nordisk

    Jul 29, 2025 · Inside Novo Nordisk Corporate Governance Our corporate governance practices take into consideration applicable regulations, corporate governance codes and the Novo …

  8. R&D pipeline - Novo Nordisk

    At Novo Nordisk, our R&D pipeline reflects our long-standing commitment to driving change to defeat diabetes and other serious chronic conditions.

  9. Novo Nordisk share information for private investors

    On this page you can see historic share prices, calculate return on an investment, find information about stock quotes and American Depository Receipts (ADRs) and get an overview of the …

  10. Press releases - Novo Nordisk

    Jul 29, 2025 · European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors

Refresh